Search Result
Results for "
DMG-PEG2000
" in MedChemExpress (MCE) Product Catalog:
15
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-112764
-
|
|
Liposome
|
Metabolic Disease
|
|
DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
-
- HY-167036
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-Mal is a pegylated lipid with a molecular weight of 2000. DMG-PEG-Mal serves as a component of lipid nanoparticles for mRNA delivery .
|
-
-
- HY-174264
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-NHS is a polyethylene glycol lipid with a molecular weight of 2000, which can be used to construct novel drug delivery systems that confer mucoadhesive and cell-targeting capabilities to lipid nanoparticles .
|
-
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
-
- HY-112764GL
-
|
|
Liposome
|
Metabolic Disease
|
|
DMG-PEG 2000 (GMP Like) is DMG-PEG 2000 (HY-112764) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
-
- HY-W1123934A
-
-
-
- HY-W1123940A
-
-
-
- HY-W590555
-
|
|
Liposome
|
Cancer
|
|
Thiol-PEG2000-DMG is a phospholipid polyPEG which can be used to prepare liposomes or nanoparticles. The terminal thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc.
|
-
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
-
- HY-182903A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-Mannose is a conjugate composed of dimyristoylglycerol (DMG), a PEG chain, and terminal mannose. DMG-PEG2000-Mannose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of mannose, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-183196A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG2000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-183398A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-CHO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal aldehyde group (-CHO). DMG-PEG2000-CHO combines the membrane compatibility of phospholipids with the flexibility of hydroxyl modification, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-200288
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-COOH is a conjugate composed of DMG, a PEG chain, and a terminal carboxyl group (-COOH). The carboxyl group in DMG-PEG2000-COOH can form an amide bond with a primary amine via EDC/NHS activation, enabling targeted modification of liposomes/nanoparticles.
|
-
-
- HY-183191A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-Alkyne is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal alkyne group. DMG-PEG2000-Alkyne combines the membrane compatibility of phospholipids with the high reactivity of the alkyne group in click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-183195A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-183156A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-Glucose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal glucose. DMG-PEG2000-Glucose combines the membrane compatibility of phospholipids with glucose as an active site for sugar recognition or subsequent coupling reactions, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-183195B
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
-
- HY-W1048669H
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Biotin-PEG2000-DMG is a compound composed of biotin, PEG, and myristoyl-sn-glycerol, used for drug delivery. Biotin forms a stable non-covalent bond with streptavidin.
|
-
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-112764GL
-
|
|
Fluorescent Dyes
|
|
DMG-PEG 2000 (GMP Like) is DMG-PEG 2000 (HY-112764) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
| Cat. No. |
Product Name |
Type |
-
- HY-112764
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
- HY-167036
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-Mal is a pegylated lipid with a molecular weight of 2000. DMG-PEG-Mal serves as a component of lipid nanoparticles for mRNA delivery .
|
-
- HY-174264
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-NHS is a polyethylene glycol lipid with a molecular weight of 2000, which can be used to construct novel drug delivery systems that confer mucoadhesive and cell-targeting capabilities to lipid nanoparticles .
|
-
- HY-112764GL
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG 2000 (GMP Like) is DMG-PEG 2000 (HY-112764) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
- HY-W1123934A
-
-
- HY-W1123940A
-
-
- HY-182903A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-Mannose is a conjugate composed of dimyristoylglycerol (DMG), a PEG chain, and terminal mannose. DMG-PEG2000-Mannose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of mannose, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183196A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG2000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183398A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-CHO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal aldehyde group (-CHO). DMG-PEG2000-CHO combines the membrane compatibility of phospholipids with the flexibility of hydroxyl modification, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-200288
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-COOH is a conjugate composed of DMG, a PEG chain, and a terminal carboxyl group (-COOH). The carboxyl group in DMG-PEG2000-COOH can form an amide bond with a primary amine via EDC/NHS activation, enabling targeted modification of liposomes/nanoparticles.
|
-
- HY-183191A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-Alkyne is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal alkyne group. DMG-PEG2000-Alkyne combines the membrane compatibility of phospholipids with the high reactivity of the alkyne group in click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183195A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183156A
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-Glucose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal glucose. DMG-PEG2000-Glucose combines the membrane compatibility of phospholipids with glucose as an active site for sugar recognition or subsequent coupling reactions, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183195B
-
|
|
Biochemical Assay Reagents
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-W1048669H
-
|
|
Biochemical Assay Reagents
|
|
Biotin-PEG2000-DMG is a compound composed of biotin, PEG, and myristoyl-sn-glycerol, used for drug delivery. Biotin forms a stable non-covalent bond with streptavidin.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10392AF
-
|
|
Wnt
β-catenin
|
Cancer
|
|
fStAx-35R TFA is the hydrocarbon-stapled peptide. fStAx-35R TFA inhibits Wnt/β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. fStAx-35R TFA can be used in cancer research .
|
-
- HY-P10896
-
|
|
Bombesin Receptor
|
Cancer
|
|
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P3252AS
-
|
|
Isotope-Labeled Compounds
Complement System
|
Inflammation/Immunology
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P3252AS
-
|
|
|
Pegcetacoplan- 13C3, 15N TFA is the 13C- and 15N-labeled Pegcetacoplan TFA. Pegcetacoplan is a pegylated complement C3/C3b inhibitor. Pegcetacoplan acts by specifically binding to and inhibiting C3 and C3b, thereby suppressing the complement cascade at its proximal stage. Pegcetacoplan is not a known inhibitor or inducer of CYP450 isoenzymes. Pegcetacoplan can be used for the research of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and age-related macular degeneration (AMD).
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-183191A
-
|
|
|
Alkynes
|
|
DMG-PEG2000-Alkyne is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal alkyne group. DMG-PEG2000-Alkyne combines the membrane compatibility of phospholipids with the high reactivity of the alkyne group in click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183195A
-
|
|
|
DBCO
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
-
- HY-183195B
-
|
|
|
DBCO
|
|
DMG-PEG2000-DBCO is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and a terminal dibenzocyclooctylene (DBCO). DMG-PEG2000-DBCO combines the membrane compatibility of phospholipids with the high reactivity of the DBCO group in copper-free click chemistry, making it suitable for research in biomaterial construction and drug delivery.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-112764
-
|
|
|
Pegylated Lipids
|
|
DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
- HY-167036
-
|
|
|
Pegylated Lipids
|
|
DMG-PEG2000-Mal is a pegylated lipid with a molecular weight of 2000. DMG-PEG-Mal serves as a component of lipid nanoparticles for mRNA delivery .
|
-
- HY-174264
-
|
|
|
Pegylated Lipids
|
|
DMG-PEG2000-NHS is a polyethylene glycol lipid with a molecular weight of 2000, which can be used to construct novel drug delivery systems that confer mucoadhesive and cell-targeting capabilities to lipid nanoparticles .
|
-
- HY-W1123934A
-
|
|
|
Pegylated Lipids
|
|
DMG-PEG2000-SH is a PEG derivative that can be used to construct drug delivery vehicles.
|
-
- HY-W1123940A
-
|
|
|
Pegylated Lipids
|
|
DMG-PEG2000-OH is a PEG derivative that can be used to construct drug delivery vehicles.
|
-
- HY-W590555
-
|
|
|
Pegylated Lipids
|
|
Thiol-PEG2000-DMG is a phospholipid polyPEG which can be used to prepare liposomes or nanoparticles. The terminal thiol group reacts with maleimide, OPSS, vinylsulfone and transition metal surfaces including gold, silver, etc.
|
-
- HY-W1048669H
-
|
|
|
Pegylated Lipids
|
|
Biotin-PEG2000-DMG is a compound composed of biotin, PEG, and myristoyl-sn-glycerol, used for drug delivery. Biotin forms a stable non-covalent bond with streptavidin.
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-112764GL
-
|
|
Liposome
|
Metabolic Disease
|
|
DMG-PEG 2000 (GMP Like) is DMG-PEG 2000 (HY-112764) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DMG-PEG 2000 is used for the preparation of liposome for siRNA delivery with improved transfection efficiency in vitro. DMG-PEG 2000 is also used for the lipid nanoparticle for an oral plasmid DNA delivery approach in vivo through a facile surface modification to improve the mucus permeability and delivery efficiency of the nanoparticles .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
